MedTrace Logo

Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia

NCT01315587 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-09-01

No results posted yet for this study

Summary

The pilot studies have showed that theta burst stimulation (TBS) can have the more rapid and durable effects to the apply traditional rTMS protocols. The aim of this study is to investigate the effect of repetitive TMS and theta burst in reduction of negative symptoms and remission of cognitive functioning in patients with schizophrenia. In a randomized, double blind clinical trials, 30 patients with schizophrenia in Razi psychiatric hospital will be assigned to receive repetitive TMS; theta burst, or sham TMS, daily; for 20 sessions. The negative symptoms and cognitive functioning will be assessed before the treatment (pre test) during the treatment (session 10), and after the treatment (post test).QEEG and LORETA apply before and after rTMS in all subjects.

Conditions

Interventions

DEVICE

repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )

* 3 pulses at 50Hz repeated each 200 ms for 2 seconds * 80% MT * 20 days treatment

DEVICE

repetitive Transcranial Magnetic Stimulation (Magstim rapid2)

LDLPFC 110% MT 15 Hz 20 days

DEVICE

repetitive Transcranial Magnetic Stimulation(Magstim rapid2)

Placebo treatment: Sham coil

Sponsors & Collaborators

  • University of Tehran

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-11-30
Completion
2017-01-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01315587 on ClinicalTrials.gov